Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Howard Hughes Medical Institute, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Cell Metab. 2019 Feb 5;29(2):246-253. doi: 10.1016/j.cmet.2019.01.004.
It has been more than a dozen years since FGF21 burst on the metabolism field in a paper showing that its pharmacologic administration caused weight loss and improved insulin sensitivity and lipoprotein profiles in obese rodents. Since then, FGF21 analogs have advanced all the way to clinical trials, and much progress has been made in understanding FGF21's pharmacology and physiology. In this Perspective, we highlight some of the interesting themes that have emerged from this first dozen years of FGF21 research, including its roles in autocrine/paracrine and endocrine responses to metabolic stress.
自 FGF21 在一篇论文中横空出世以来，已经过去了十多个年头，该论文表明其药物治疗可导致肥胖啮齿动物体重减轻，并改善胰岛素敏感性和脂蛋白谱。从那时起，FGF21 类似物一路推进到临床试验，并且在理解 FGF21 的药理学和生理学方面取得了很大进展。在本观点中，我们强调了从 FGF21 研究的最初十二年中出现的一些有趣主题，包括其在代谢应激的自分泌/旁分泌和内分泌反应中的作用。
